AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large

Daiichi Sankyo made clear its ambition to transform into a global oncology leader when it wooed Ken Takeshita from Kite Pharma to become its …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As­traZeneca’s big ADC part­ner pledges to pour $13.6B in­to can­cer R&D over next 5 years — and En­her­tu looms large